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AT A GLANCE COMMENTARY 
Scientific Knowledge on the Subject 
Several studies have suggested that gene-environment interactions play an important role in the occurrence of 
asthma and allergy. Genes dependent on the innate immunity pathway are obvious candidates for the 
understanding of the protective effects of exposure to microbial agents on allergy and asthma. 
 
What This Study Adds to the Field 
TLR2 and CD14 SNPs were associated with asthma and atopic asthma respectively. Variation in CD14, TLR2, 
TLR4, and TLR9 genes modified associations between country living during childhood and asthma, in particular 
among atopic subjects. 
 
ABSTRACT 
Rationale: It has been shown that country living protects against asthma, which may be explained by microbial 
exposures. Objectives: To study whether single nucleotide polymorphisms (SNPs) in CD14 and Toll-like 
receptor (TLR) 2, TLR4 and TLR9 genes are associated with asthma in adults, and whether these SNPs modify 
associations between country living and asthma. Methods: Twenty-five SNPs in CD14, TLR2, TLR4, and TLR9 
genes were genotyped in adult subjects from the French Epidemiological study on the Genetics and 
Environment of Asthma, Bronchial Hyperresponsiveness, and Atopy (EGEA). We conducted a case-control 
analysis on unrelated subjects (239 asthmatics and 596 non asthmatics), and a family based association test 
(FBAT) in 192 families ascertained through asthmatic probands. Measurements and Main Results: The 
TLR2/+596 C allele was associated with an increased risk for asthma in both case-control and family-based 
analyses (under a dominant model, OR [95%CI]=1.91 [1.34-2.72], P=.0003; z statistics from FBAT=2.48, 
P=.01). In skin prick test (SPT) positive subjects, the CD14/-260 C allele was negatively associated with asthma 
(additive model, OR[95%CI]=0.66 [0.48-0.91]). Significant gene-environment interactions between variation in 
CD14 and TLR genes and country living during childhood were found for ten SNPs. In SPT positive subjects 
carrying CD14/-260 CC, country living protected against asthma (OR=0.32 [0.12-0.85]), whereas country living 
was not associated with asthma in atopics carrying CD14/-260 T (OR=1.11 [0.65-1.90]) (gene-environment 
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interaction P<.05). Conclusions: TLR2 and CD14 SNPs were associated with asthma and atopic asthma 
respectively. In addition, CD14, TLR2, TLR4, and TLR9 SNPs modified associations between country living and 
asthma. 
Abstract: 249 words 
Keywords: asthma; atopy; epidemiology; gene-environment interaction; hygiene hypothesis 
INTRODUCTION 
Epidemiological studies have shown a lower prevalence of asthma and allergic sensitization in children and 
adults who lived on a farm or in a rural area during childhood (1-6). According to the hygiene hypothesis, the 
development of allergic disease may be influenced by bacterial and viral infections, and environmental exposure 
to noninfectious microbial agents such as endotoxin – which are abundantly present in the farm environment (7). 
Both exposure to environmental factors and genetic susceptibility play a role in the occurrence of asthma and 
allergy. Therefore, genes dependent of the innate immunity pathway are obvious candidates for the 
understanding of the protective effects of exposure to microbial agents on allergy and asthma. Indeed, several 
single nucleotide polymorphisms (SNPs) in genes encoding pattern recognition receptors such as CD14 and 
Toll-like receptors (TLR) have been associated with atopic sensitization and asthma (8, 9). The first report by 
Baldini et al. (10) on the functional (11) CD14 C -159 T SNP (C -260 T when counting from the translation start 
site) has shown increased levels of circulating soluble CD14 (sCD14) in TT homozygotes, and a lower number 
of positive skin prick tests in atopic children carrying this genotype. Although subsequent studies have often 
replicated the association between CD14/-260 T and increased sCD14, results on atopic sensitization have been 
conflicting and results for asthma were mainly negative (9, 12-14). Several studies have suggested that gene-
environment interactions play an important role, since associations between CD14/-260 genotype and allergy 
and asthma-related outcomes have been shown to depend on the level of microbial exposures (15). A few 
studies have also shown gene-environment interactions in relation to SNPs in TLR2 and TLR4 genes, and other 
SNPs in the CD14 gene (-1721 showing a high linkage disequilibrium with CD14/-260) (16-18).  
In the French Epidemiological study on the Genetics and Environment of Asthma, Bronchial 
Hyperresponsiveness, and Atopy (EGEA) a lower prevalence of asthma has been shown in adults who lived in 
the country during childhood (3). The purpose of the present study was to investigate whether SNPs in the 
candidate genes CD14, TLR2, TLR4, and TLR9 are associated with asthma in adults from the EGEA study by 
conducting a case-control analysis on unrelated subjects and a family based association test (19). We further 
investigated whether these SNPs modify associations between living in the country and asthma. Studies in 
children and adults have shown that exposure to endotoxin and other microbial agents may protect against 
asthma or wheeze in atopic subjects, whereas increased exposure may be a risk factor for nonatopic asthma or 
wheeze (20-22). Therefore, the role of atopy was evaluated by conducting separate analyses for atopic and 
nonatopic subjects. Some of the results presented here have been previously reported in the form of an abstract 
(23). 
 
METHODS 
Study population and design 
The design of EGEA combines a case-control study and a family study of adult and childhood asthma. The 
design, ascertainment of asthmatic cases, and descriptive characteristics have been described earlier (24-27). 
Briefly, asthmatic patients (age 7-70 years) were recruited from six chest clinics in five French cities. Family 
members of asthmatic probands were included, either by including the proband’s parents and siblings, or by 
including the proband’s spouse and children. Controls were population-based. Inclusion criteria used to define 
asthma in probands were based on self-reported answers to the four questions “Have you ever had attacks of 
breathlessness at rest with wheezing?”, “Have you ever had asthma attacks?”, “Was this diagnosis confirmed by 
a physician?”, and “Have you had an asthma attack in the last 12 months?”, or a positive response to at least two 
questions and a positive expertise of their medical record (25). Asthma in relatives of probands was defined as a 
positive answer to the question “Have you ever had attacks of breathlessness at rest with wheezing?” or “Have 
you ever had asthma attacks?” (25). In the present study, “asthmatics” were defined as probands and relatives 
with asthma, “nonasthmatics” as population-based controls and relatives without asthma. Atopy was defined as 
a positive skin prick test (SPT) to one of the 11 common allergens tested (28). Country living during childhood 
was defined as a positive answer to the question “Have you ever lived in the country for at least one year?”, and 
being 16 years of age or younger when beginning to live in the country (3). Age 16 was chosen as a cut-off 
because in the initial study (3), living in the country before age 16 was most strongly associated with a reduced 
prevalence of asthma. Sensitivity analyses were conducted using country living before being 1 year of age, and 
additional information on the definition of country living is given in the online data supplement. 
A case-control analysis was conducted in 825 genetically unrelated adults from the parental generation (aged 
27-70 years), i.e. adult probands and their spouses, parents of probands from families where the proband is 
offspring, and population-based controls from the same generation. In addition, a family-based analysis was 
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conducted in 708 adult subjects from 192 families, comprising 378 parents who were included in the case-
control analysis as well, and 330 adult offspring subjects who were not included in the analysis among unrelated 
subjects. All participants gave written informed consent. Additional information is given in the online data 
supplement. 
 
Genotyping 
Twenty-five SNPs belonging to the four candidate genes considered were selected using a tagging approach: 
CD14 (5 SNPs), TLR2 (5 SNPs), TLR4 (10 SNPs) and TLR9 (5 SNPs). This set of SNPs allowed us to capture 
the majority of common haplotype variation of these four genes (i.e., haplotype with a frequency > 5%). Details 
on genotyping are given in the online data supplement. 
 
Statistical analysis 
In the 825 genetically unrelated adults, odds ratios (ORs) for associations between genotype and asthma were 
calculated by generalized estimating equations (GEE model; Proc GENMOD using SAS statistical software) to 
adjust for dependence between subjects sharing the same household (probands and their spouses, and mothers 
and fathers of probands). ORs were adjusted for age and sex. The effect of each SNP on disease was tested 
under a general genetic model (2-degrees-of-freedom-test) and ORs were calculated using homozygotes for the 
most frequent allele as reference group. In addition, dominant, recessive, and additive genetic models were 
considered and the best-fitting model was selected (likelihood ratio test). We tested the null hypothesis that 
effects of genotype and country living on asthma were independent by including an interaction term in the 
model (gene-environment interaction) and testing the significance (GEE model, Z-score). False Discovery Rate 
(FDR) adjusted P-values were calculated to take multiple comparisons (n=25 SNPs) into account (29). 
In order to confirm associations among unrelated subjects, a family-based association test, as implemented in 
FBAT (30) was performed as a complementary method to test for association between asthma and genetic 
polymorphisms. Details on the FBAT method are given in the online data supplement.  
 
RESULTS 
Identification numbers, position, and minor allele frequencies of studied SNPs are shown in Table E2 in the 
online data supplement. All SNPs were in Hardy-Weinberg equilibrium (P>.05). Tables E3-E6 in the online 
data supplement show linkage disequilibrium (LD) between polymorphisms for the four genes under study. 
 Characteristics of nonasthmatic (n=586) and asthmatic (n=239) subjects are shown in Table I. Living in the 
country during childhood was associated with a lower prevalence of asthma with an OR of 0.67 (0.48-0.92) 
(before 16y) and 0.72 (0.52-1.01) (before 1y, P=.06), which confirmed the earlier report in a different 
subpopulation of the EGEA study (3). Adjusting for age, sex, and smoking habits did not change the association.  
 
Association between CD14, TLR2, TLR4, and TLR9 genetic polymorphisms and asthma 
The genotypic distribution of CD14, TLR2, TLR4, and TLR9 SNPs and the associations between these 
polymorphisms and asthma in the 825 unrelated subjects are shown in Tables E7-E10 in the online data 
supplement. Carrying the TLR2/+596 C allele was associated with an increased risk for asthma (OR (95%CI) = 
1.91 (1.34-2.72); P=.0003, P value adjusted for multiple comparisons =.008). Two other TLR2 SNPs, TLR2/-
24438 and rs2289318, and two TLR9 SNPs, rs353547 and TLR9/+2848, were also associated with asthma, but 
not significantly after adjusting for multiple comparisons. Since low LD was observed among the three TLR2 
SNPs on the one hand (LD coefficient r
2
≤0.34; Table E4) and between the two TLR9 SNPs on the other hand 
(LD coefficient r
2
=0.53; Table E6), we conducted two separate multivariate-SNP analyses by including these 
polymorphisms in the regression model. TLR2/+596 was the only SNP significantly associated with asthma in 
the model testing for three TLR2 markers. Estimates for each TLR9 SNP in the multiple regression model were 
similar to those in the univariate model. However, none of them was significant after mutual adjustment. 
Associations between genotype and asthma were not different for men and women (interaction P>.10 for all 
SNPs). Similar results were obtained when either population-based controls (n=117) or non-asthmatic family 
members (n=469) were excluded from the control group (data not shown).The positive association between the 
TLR2/+596 C allele and asthma under a dominant model was confirmed by a family-based association test in 
192 families (Z=2.48; P=.01, FBAT). In the family-based analysis, asthma outcome of 330 offspring subjects 
determined the magnitude of the test statistic, whereas the case-control analyses in the 825 genetically unrelated 
subjects as described above included only the parental generation. For other SNPs no significant association 
was found using FBAT (P>.05; data not shown). 
In the 825 genetically unrelated subjects, the influence of TLR2/+596 on associations between other SNPs and 
asthma (i.e. gene-gene interactions) was assessed by including an interaction term in the model and testing the 
significance (GEE model, Z-score). For three SNPs (CD14/+1188 and two TLR9 SNPs), a significant 
interaction with TLR2/+596 genotype was found (Table II), showing significant associations between these 
SNPs and asthma in TLR2/+596 TT homozygotes, but ORs around 1 in subjects carrying TLR2/+596 C. 
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Separate analyses were conducted for atopic and nonatopic subjects. Associations between genotype and 
asthma outcomes for 11 SNPs associated with at least one of the asthma outcomes are presented in Table III 
(unadjusted P<.05 for 11 SNPs, FDR-adjusted P<.05 for 6 SNPs). Carrying the TLR2/+596 C allele was a 
significant risk factor for asthma in atopic subjects (OR 2.39, P=.0006), whereas a positive but not significant 
association was found in nonatopic subjects (OR 1.55, P=.13). The CD14/-260 C allele protected against asthma 
in atopic subjects with an OR of 0.66 (0.48-0.91). Four other CD14 SNPs were also significantly associated with 
a lower risk of asthma in atopic subjects, and for these SNPs, associations differed significantly from those 
observed in non-atopic subjects, who had ORs around 1 (gene-atopy interaction P<.05). Atopic subjects 
carrying a protective allele for each CD14 SNP had significantly less asthma compared with subjects carrying 
none of the protective alleles, with an OR of 0.34 (0.18-0.67). Carrying a protective allele for one to four CD14 
SNPs showed an OR of 0.64 (0.37-1.16) compared with subjects carrying none. Multiple regression models 
including more than one CD14 SNP showed independent effects that were similar in size for each different 
SNP, thus the effect was not dominated by one particular SNP. 
 
Role of CD14, TLR2, TLR4, and TLR9 genetic polymorphisms in the associations between living in the 
country and asthma 
Gene-environment interactions between 10 SNPs and living in the country during childhood were found for at 
least one of the asthma outcomes (unadjusted P-value for interaction <.05 for 10 SNPs, FDR-adjusted P<.10 for 
6 SNPs; Table IV). In atopic subjects with CD14/-260 CC genotype, country living protected against asthma 
(OR 0.32), whereas country living was not associated with asthma in atopics carrying the CD14/-260 T allele 
(OR 1.11). Conversely, in non-atopic subjects carrying CD14/-260 CC, country living was not associated with 
asthma (OR 1.33), whereas country living was associated with a lower risk of asthma in non-atopic subjects 
carrying the CD14/-260 T allele (OR 0.41). For this SNP, a significant second-order interaction term (gene x 
environment x atopy) was found (P=.005). 
In atopics, gene-environment interactions were found as well for three other CD14 SNPs, one TLR4 SNP, and 
one TLR9 SNP (all FDR-adjusted P-values for interaction were borderline significant). In nonatopic subjects, 
gene-environment interactions were found for four SNPs, including TLR2/+596. In nonatopic carriers of the 
TLR2/+596 C allele, country life protected against asthma. Alternatively, when the results were stratified for 
living in the country, carrying at least one TLR2/+596 C allele (CC/CT vs TT) was a risk factor for asthma in 
nonatopic subjects who had not grown up in the country with an OR of 2.94 (1.16-7.41), but not in those who 
had grown up in the country (OR 0.77 (0.35-1.70)). 
Sensitivity analyses using 1 year of age as a cut-off for beginning to live in the country showed very similar 
results, but the P-values for interaction were less often statistically significant, especially for atopic asthma 
(Table E11 in the online data supplement).  
 
DISCUSSION 
In the present study, an association was found between the TLR2/+596 polymorphism and asthma among 
French adults from the EGEA study. The well-studied CD14/-260 SNP was associated with asthma in SPT 
positive subjects – once again confirming the importance of this SNP in the occurrence of allergy and asthma 
related phenotypes. Gene-environment interactions were found between ten SNPs in candidate genes CD14, 
TLR4, TLR2, and TLR9 and living in the country during childhood, which was presumed to represent higher 
exposures to various microbial agents. Main effects and gene-environment interactions were stronger in atopic 
subjects than in non-atopic subjects. Significant interactions between CD14 SNPs and atopy were found in the 
association with asthma, moreover for CD14/-260, a significant interaction between genotype, atopy, and 
country living was found. 
Eder et al. found that a SNP in TLR2 (A -16934 T) was associated with asthma, atopy, and hay fever in 
children of farmers (16). On the other hand, two studies investigating genetic variation in TLR2 reported no 
association with childhood-onset atopic asthma in a Japanese population (31), and no association with atopy or 
new-onset asthma in young Danish farmers (32). In the present study, we observed replication for the 
association between TLR2/+596 and asthma in case-control and family-based analyses. In the case-control 
analysis only the parental generation was included, whereas in the family-based analysis, genotype and asthma 
outcome of offspring determined the magnitude of the test statistic. Thus, results of the two different analyses 
were based on a different population within the EGEA study, which substantiates findings on TLR2. Moreover, 
although we tested a large number of SNPs in four candidate genes which increases the risk for false positive 
results, the findings on TLR2/+596 were still statistically significant after adjusting for multiple comparisons. 
TLR2 is involved in the recognition of microbial motifs of a wide range of Gram-positive microorganisms, 
mycobacteria and yeast, and exposures to these micoorganisms are likely to be higher in rural than in urban 
areas. We can only speculate on a possible mechanism explaining our findings, as the functional significance of 
TLR2/+596 is so far unknown. A possible explanation could be a lower expression of TLR2 on the surface of 
innate immune cells in carriers of the TLR2/+596C allele. As a consequence, carriers of TLR2/+596C would 
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benefit less from the protective effects of environmental exposures to TLR2 ligands on asthma. Further analyses 
of different asthma outcomes showed that TLR2/+596C was in particular associated with asthma in SPT 
positive subjects, whereas in nonatopic subjects, a significant interaction with childhood environment was 
found, showing that TLR2/+596C was only a risk factor for asthma in nonatopic subjects who had not grown up 
in the country. Thus, variation in TLR2 appears to be associated with asthma, but environmental exposure, 
asthma subphenotype, and also interactions with other genes such as CD14 and TLR9 were shown to play a role.  
TLR9 is a receptor for bacterial CpG DNA motifs, which have been found in increased levels in farm barn 
dust and dust from rural homes (33). Only few studies have investigated TLR9 SNPs in relation to allergy or 
asthma, showing inconsistent results (31, 34, 35). In the present study, only minor associations with asthma 
were found for TLR9 SNPs when other factors were not taken into account. However, significant gene-gene 
interactions with the TLR2/+596 SNP were found, showing effects of two TLR9 SNPs on asthma in TLR2/+596 
TT subjects. Since TLR9 and TLR2 have different ligands, this finding might reflect an interactive effect of 
multiple microbial exposures.  
In contrast to TLR2 and TLR9, which have not been studied widely in relation to asthma or allergic outcomes, 
CD14 is one of the best established susceptibility genes for asthma-related phenotypes such as allergic 
sensitization and total IgE (36). Studies investigating asthma in relation to CD14/-260 have often been negative, 
whereas either the C allele or T allele were alternately found to be a risk factor for allergic sensitization, number 
of positive SPT, or increased total IgE (9, 15). In the present study, CD14 polymorphisms protected against 
asthma, but only in atopic subjects, showing significant gene-atopy interactions.  
In various studies, inverse associations between house dust endotoxin and allergic sensitization, total serum 
IgE, and asthma have been shown to be strongest in CD14/-260 CC homozygotes (15, 37, 38). In the present 
study, the inverse relationship between a rural childhood and asthma in atopic adults was also strongest in 
CD14/-260 CC subjects, and a significant gene-environment interaction was found. This apparent replication of 
a gene-environment interaction is remarkable, given the different phenotypes, age of study subjects, timing of 
exposure, study region, and exposure definitions across these studies. Conversely, in three other studies, the 
CD14/-260 TT genotype protected against atopic dermatitis, atopy, and increased IgE, especially in children 
with a dog in the home (39, 40), and in adults or young farmers who lived on a farm during childhood (32, 41). 
Gene-environment interactions are therefore likely to depend on qualitative and quantitative characteristics of 
environmental exposure, but also on phenotype, interactions with other genes, and on the age of study subjects 
(9, 36). The importance of atopy as an effect modifier in the present study underlines the complex 
interrelationships between environmental exposures, genetic variation in CD14, and asthma. 
The fact that interactions were found between a rural childhood and polymorphisms in genes encoding four 
different pattern recognition receptors that become activated by a wide array of ligands, suggests that the 
protective effect of living in the country is – at least partly – a result of increased microbial exposures. In the 
present study, living in the country was used as a proxy for high exposure to microbial agents during childhood, 
since measured domestic endotoxin levels or more specific information regarding farm (animal) exposures was 
not available. Nevertheless, in the EGEA study it has been demonstrated that several lifestyle factors differed 
substantially between subjects who ever lived in rural communities and subjects who had always lived in urban 
regions: for instance, rural life was associated with factors such as using wood for heating, household size, and 
the presence of pets (3). Self-reported country living during childhood was also associated with parental farming 
and residential history (see Table E1 in the online data supplement). One could argue that concentrations of 
microbial agents in dust collected in rural homes are lower compared with dust from farm homes (42), and in 
our study only few subjects had farming parents. However, levels of microbial exposures in rural households 
have been found to be higher than exposure levels in urban homes (33). Moreover, considering the fact that 
most of the present study subjects were born in the 1940s/50s, it is likely that other relevant factors such as raw 
milk consumption, and exposure to stables and livestock were relatively common among those living in the 
country during their childhood compared with those in urban areas.  
For country living during childhood, a 16 year cut-off was used. When we considered subjects with early-life 
rural exposures (before 1 year), very similar results were obtained, although gene-environment interactions were 
less often statistically significant. This may partly be due to a decreased power because of the lower number of 
early-life rural exposed subjects. It is also possible that rural exposures later in childhood may have a protective 
effect on asthma as well, which is suggested by the observed stronger relationship between country living and 
asthma when using 16 years as a cut-off. 
In conclusion, TLR2 and CD14 are important genes for asthma in adults. Variation in CD14, TLR2, TLR4, and 
TLR9 genes modified associations between country living during childhood and asthma, in particular for asthma 
in atopic subjects. 
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TABLE I. Characteristics of the study population 
 Nonasthmatics Asthmatics P 
n 586 239  
Age, y, mean ± sd 47.1 ± 8.0 46.0 ± 8.8 .07 
Males, n (%) 293 (50.0) 123 (51.5) .70 
Smoking habits    
 Never smokers, n (%) 258 (44.3) 104 (43.9) .01 
 Exsmokers, n (%) 178 (30.5) 93 (39.2)  
 Current smokers, n (%) 147 (25.2) 40 (16.9)  
Living in the country during childhood, n (%)
*
 254 (55.0) 105 (44.9) .01 
 Number of years during childhood, y, mean ± sd
¶
 11.2 ± 5.2 11.1 ± 4.9 .97 
Living in the country before age 1 year, n (%)
*
 165 (35.7) 67 (28.6) .06 
Atopy, n (%) 182 (31.8) 148 (64.4) <.0001 
*
 population-based controls
 
(n=117) excluded 
¶ 
Among the 254 nonasthmatics and 105 asthmatics who lived in the country during childhood. 
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TABLE II. Associations between CD14 and TLR9 SNPs and asthma for SNPs showing significant gene-gene interactions with TLR2/+596 
   Asthma (OR (95% CI)) P interaction 
SNP Model All subjects (n=825)
#
 
TLR2/+596 TT 
(n=259)
#
 
TLR2/+596 CT/CC 
(n=529)
#
 
Unadjusted 
FDR 
adjusted 
CD14/+1188 CG+GG vs CC (ref) 0.72 (0.49-1.06) 0.30 (0.11-0.81) 0.93 (0.60-1.45) .03 .16 
TLR9 rs352143 AG+GG vs AA (ref) 1.15 (0.85-1.55) 2.31 (1.24-4.30) 0.95 (0.66-1.38) .02 .15 
TLR9 rs352163 T allele 
¶
 0.87 (0.70-1.09) 0.48 (0.30-0.74) 1.04 (0.80-1.35) .002 .04 
¶ 
Additive genetic model, the genotype was categorized into a three level variable for the number of minor alleles (0,1,2). 
Ref: reference genotype coded as 0. 
Bold: p<0.05. 
#
 Exact numbers of genotyped subjects for each SNP are given in Table E2. TLR2/+596 was genotyped in 788 subjects. 
 
TABLE III. Associations between CD14, TLR2, TLR4, and TLR9 SNPs and asthma for SNPs significantly associated with at least one of the asthma outcomes 
   OR (95% CI) 
Gene SNP Model Asthma 
Asthma in atopic 
subjects 
Asthma in nonatopic 
subjects 
CD14 -260 C allele 
¶
 0.81 (0.65-1.01) 0.66 (0.48-0.91)
**
 0.93 (0.65-1.33) 
 +1188 CG+GG vs CC (ref) 0.72 (0.49-1.06) 0.44 (0.25-0.78)
**
 1.00 (0.56-1.82) 
 +1341 AC+AA vs CC (ref) 0.77 (0.56-1.06) 0.50 (0.31-0.81)
**
 1.02 (0.62-1.69) 
 rs778584 T allele 
¶
 0.86 (0.69-1.06) 0.62 (0.46-0.85)
**
 1.09 (0.77-1.52) 
 rs778583 CT+TT vs CC (ref) 0.80 (0.59-1.09) 0.47 (0.29-0.75)
**
 1.11 (0.69-1.80) 
      
TLR2 -24438 GG vs AA+AG (ref) 0.57 (0.36-0.90) 0.47 (0.25-0.89)
*
 0.66 (0.32-1.36) 
 +596 CT+CC vs TT (ref) 1.91 (1.34-2.72)
**
 2.39 (1.45-3.94)
**
 1.55 (0.88-2.73) 
 +1349 C allele 
¶
 1.30 (0.90-1.88) 1.04 (0.55-1.98) 1.92 (1.17-3.15) 
 rs2289318 CG+GG vs CC (ref) 1.40 (1.01-1.94) 1.61 (1.01-2.56) 0.83 (0.48-1.43) 
      
TLR9 rs353547 AG+AA vs GG (ref) 1.43 (1.03-1.99) 1.27 (0.79-2.06) 1.43 (0.86-2.38) 
 +2848 AA vs GG+AG (ref) 0.65 (0.43-0.99) 0.62 (0.34-1.13) 0.77 (0.40-1.46) 
Bold: p<0.05, not adjusted for multiple comparisons; 
*
 p<0.10, FDR adjusted p value; 
**
 p<0.05, FDR adjusted p value 
¶ 
Additive genetic model, the genotype was categorized into a three level variable for the number of minor alleles (0,1,2). 
Ref: reference genotype coded as 0. 
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TABLE IV. Gene-environment interactions between CD14, TLR2, TLR4, and TLR9 SNPs and country living during childhood in asthma outcomes, shown as associations 
between country living and asthma, stratified by genotype 
   Living in the country during childhood, OR (95% CI) 
Gene SNP  Genotype Asthma 
Asthma in atopic 
subjects 
Asthma in nonatopic 
subjects 
CD14 -260 TT+CT 0.66 (0.45-0.97) 1.11 (0.65-1.90)
*
 0.41 (0.22-0.79) 
  CC 0.63 (0.32-1.24) 0.32 (0.12-0.85) 1.33 (0.46-3.84) 
 +1341 CC 0.92 (0.59-1.44) 1.59 (0.81-3.13)
*
 0.75 (0.36-1.55) 
  AC+AA 0.44 (0.26-0.73) 0.48 (0.23-0.99) 0.42 (0.18-1.00) 
 rs778584 CC+CT 0.64 (0.44-0.94) 1.07 (0.63-1.82)
*
 0.42 (0.22-0.78) 
  TT 0.72 (0.38-1.40) 0.32 (0.12-0.84) 1.41 (0.51-3.87) 
 rs778583 CC 0.89 (0.58-1.37) 1.50 (0.77-2.95)
*
 0.76 (0.37-1.55) 
  CT+TT 0.47 (0.28-0.76) 0.47 (0.23-0.94) 0.48 (0.22-1.05) 
      
TLR2 -24438 AA+AG 0.63 (0.45-0.90) 0.87 (0.54-1.42) 0.47 (0.26-0.85) 
  GG 0.94 (0.38-2.33) 0.44 (0.12-1.62) 3.57 (0.58-21.8) 
 +596 TT 0.66 (0.35-1.27) 0.53 (0.20-1.35) 1.36 (0.48-3.88) 
  CT+CC 0.65 (0.43-0.97) 0.91 (0.52-1.59) 0.40 (0.20-0.78) 
 +1349 TT 0.68 (0.47-0.96) 0.78 (0.48-1.27) 0.71 (0.39-1.30) 
  CT+CC 0.57 (0.26-1.27) 0.91 (0.26-3.22) 0.23 (0.07-0.76) 
      
TLR4 rs11536889 GG 0.79 (0.54-1.15) 1.17 (0.67-2.05)
*
 0.70 (0.37-1.32) 
  CG+CC 0.43 (0.23-0.80) 0.36 (0.14-0.91) 0.36 (0.13-0.99) 
 rs7045953 AA 0.53 (0.37-0.78) 0.66 (0.38-1.13) 0.46 (0.25-0.87) 
  AG+GG 1.14 (0.62-2.11) 1.34 (0.54-3.33) 1.16 (0.43-3.10) 
      
TLR9 rs353547 GG+AG 0.72 (0.50-1.03) 1.11 (0.67-1.86)
*
 0.53 (0.29-0.95) 
  AA 0.41 (0.18-0.96) 0.18 (0.05-0.63) 1.66 (0.40-6.92) 
Bold: interaction p<0.05, not adjusted for multiple comparisons; 
*
 interaction p<0.10, FDR adjusted p value 
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CD14 and Toll-like receptor gene polymorphisms, country living, and asthma in adults 
 
Lidwien A. M. Smit, Valérie Siroux, Emmanuelle Bouzigon, Marie-Pierre Oryszczyn, Mark Lathrop, Florence 
Demenais, Francine Kauffmann, on behalf of the EGEA cooperative group 
 
 
Study population and design 
Subjects were enrolled in six chest clinics from five French cities (Grenoble, Lyon, Marseille, Montpellier, 
Paris) between 1991 and 1995. Inclusion criteria used to define asthma in probands were based on self-reported 
answers to the four questions “Have you ever had attacks of breathlessness at rest with wheezing?”, “Have you 
ever had asthma attacks?”, “Was this diagnosis confirmed by a physician?”, and “Have you had an asthma 
attack in the last 12 months?”, or a positive response to at least two questions and a positive expertise of their 
medical record (E1). All probands and their two parents were Caucasian and were born in France. All family 
members answered a detailed questionnaire based on British Medical Research Council (BMRC)/European Coal 
and Steel Community (ECSC), American Thoracic Society (ATS), and European Community Respiratory 
Health Survey (ECRHS) questionnaires. Based on the BMRC/ECSC questionnaire, asthma in relatives of 
probands was defined as a positive answer to the question “Have you ever had attacks of breathlessness at rest 
with wheezing?” or “Have you ever had asthma attacks?” (E1). Population-based controls were selected from 
electoral rolls, a surgery department, and a social security check-up center. In the present study, “asthmatics” 
were defined as probands and relatives with asthma, “nonasthmatics” as population-based controls and relatives 
without asthma. Population-based controls with asthma (n=15) were excluded from data analysis.  
Figure E1 represents a diagram describing the population used in the present analysis. As shown in Figure 
E1, a case-control analysis was conducted in genetically unrelated adults from the parental generation. 
Population-based controls were assigned to the parental generation (controls aged 40-64 yrs) or offspring 
generation (controls aged 18-47 yrs) on the basis of age in order to obtain an optimal age distribution between 
cases and controls. The study protocol was approved by the institutional ethics committee and all participants 
gave written informed consent. 
 
Country living 
The present study was restricted to adult subjects of the EGEA study because information on country living was 
only available for adults. Country living was not taken into account during recruitment, as this was not 
considered of importance when the study was designed in 1990/1991. As described earlier, the area of residence 
for asthmatic probands and their relatives was broader than for most population-based controls, reflecting the 
area of attraction of the chest clinics, and significantly more asthmatic probands were living in the country than 
population-based controls (E2). Analyses that included country living were therefore conducted in asthmatic 
probands and relatives only, excluding controls (n=117).  
Country living during childhood was defined as living in a rural area for at least one year in a row, and being 
16 years of age or younger when beginning to live in the country. In EGEA2, the 12 year follow-up of the first 
EGEA survey which has been conducted recently (between 2003 and 2006) (E3), more questions on residential 
history and farming were asked. In EGEA2 the complete residential history (at the French ‘commune’ level) 
was obtained and these data were combined with demographic statistics indicating the number of inhabitants of 
the ‘commune’. Table E1 shows that subjects with and without a rural childhood are significantly different with 
regard to farming parents and residential history. 
 
Genotyping 
Genotyping was performed using either Taqman Probes (Applied Biosystems, Foster City, CA) on an 
ABI7900HT Sequence Detection System or 1536-plex Illumina Golden Gate assay (Illumina, San Diego, CA) at 
the Centre National de Génotypage (CNG, Evry, France).  
 
FBAT 
A family-based association test, as implemented in FBAT (E4) was performed as a complementary method to 
test for association between asthma and genetic polymorphisms in the adult offspring sample. This approach 
tests
 
for the association between the phenotype and excess transmission
 
of a specific allele from parent to 
offspring. The advantage of this approach is that population
 
stratification is avoided. We used the –o option in 
FBAT program allowing to take into account affected and unaffected offspring in the analysis. Association was 
initially tested under a general model and subsequently under additive, dominant and recessive models. 
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TABLE E1. Factors related to living in the country during childhood 
 
 N complete data 
Country living during 
childhood 
  No Yes 
Born in a community <5000 inhabitants, n (%) 500 17 (7.0) 126 (49.0)
*
 
Living in a community <5000 inhabitants during 
childhood, n (%) 
500 27 (11.1) 170 (66.2)
*
 
Farming as parental occupation, n (%) 538 0 (0) 48 (17.2)
*
 
P<.0001 
 
 
 
Figure E1. Diagram describing the study population used in the case-control and family-based analysis. 
Asthmatic subjects are represented by shaded shapes. Asthmatic probands and population-based controls are 
represented by a dot. 
 
TABLE E2. SNP identification numbers, position, and minor allele frequencies 
dbSNP ID Gene 
Genomic 
location 
Position from 
translation start 
site  
Alleles 
Minor 
allele 
frequency 
N 
rs2569190 CD14 5 :139993100 -260 T/C 0.50 777 
rs4914 CD14 5 :139991652 +1188 C/G 0.12 783 
rs2563298 CD14 5 :139991499 +1341 C/A 0.27 781 
rs778584 CD14 5 :139985396  C/T 0.49 819 
rs778583 CD14 5 :139985294  C/T 0.28 822 
       
rs13150331 TLR2 4 :154819072 -24438 A/G 0.40 817 
rs3804099 TLR2 4 :154844106 +596 T/C 0.43 788 
rs3804100 TLR2 4 :154844859 +1349 T/C 0.08 822 
rs5743700 TLR2 4 :154845132 +1622 C/T 0.04 786 
rs2289318 TLR2, RNF175 4 :154853184  C/G 0.17 822 
       
rs10759930 TLR4 9 :119501442  C/T 0.41 822 
rs2737191 TLR4 9 :119502536  A/G 0.27 821 
rs4986791 TLR4 9 :119515423 
+1196, 
Thr399Ile 
C/T 0.06 792 
rs7869402 TLR4 9 :119517853  C/T 0.02 790 
rs11536889 TLR4 9 :119517952  G/C 0.17 820 
rs1927906 TLR4 9 :119519936  A/G 0.09 821 
rs1554973 TLR4 9 :119520633  T/C 0.24 817 
rs913930 TLR4 9 :119523830  T/C 0.34 820 
Population-based 
controls 
Families 
Parental 
generation 
. 
.
. .
. .
 
x
. 
Offspring 
generation 
Case-control analysis 
in  asthmatics (n=239) 
and non-asthmatics 
(n=586) of parental 
generation 
Children 
Adults 
330 subjects from 192 
families determine the 
outcome of the Family 
Based Analysis 
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rs1927905 TLR4 9 :119525129  A/G 0.06 822 
rs7045953 TLR4 9 :119525616  A/G 0.15 821 
       
rs353547 TLR9, PTK9L 3 :52243906  G/A 0.39 821 
rs11717574 TLR9, PTK9L 3 :52243286  T/C 0.15 815 
rs352143 TLR9, PTK9L 3 :52239947  A/G 0.21 822 
rs352140 TLR9 3 :52231737 +2848 G/A 0.47 778 
rs352163 TLR9, ALAS1 3 :52222150  C/T 0.47 817 
 
TABLE E3. Linkage disequilibrium (r
2
) between CD14 SNPs 
 -260 +1188 +1341 rs778584 rs778583 
-260  0.14 0.37 0.95 0.37 
+1188   0.37 0.14 0.35 
+1341    0.38 0.98 
rs778584     0.39 
rs778583      
 
TABLE E4. Linkage disequilibrium (r
2
) between TLR2 SNPs 
 -24438 +596 +1349 +1622 rs2289318 
-24438  0.34 0.05 0.03 0.05 
+596   0.11 0.06 0.26 
+1349    0 0.02 
+1622     0.23 
rs2289318      
 
TABLE E5. Linkage disequilibrium (r
2
) between TLR4 SNPs 
 rs10759930 rs2737191 Thr399Ile rs7869402 rs11536889 rs1927906 rs1554973 rs913930 rs1927905 rs7045953 
rs10759930  0.26 0.05 0.02 0.26 0.07 0.21 0.34 0.04 0.12 
rs2737191   0.03 0.01 0.06 0.04 0.11 0.65 0.02 0.06 
Thr399Ile    0 0.01 0.70 0.22 0.03 0 0.01 
rs7869402     0.01 0.25 0.08 0.01 0 0 
rs11536889      0.02 0.07 0.11 0.01 0.04 
rs1927906       0.31 0.05 0 0.01 
rs1554973        0.16 0.21 0.57 
rs913930         0.03 0.09 
rs1927905          0.37 
rs7045953           
  
TABLE E6. Linkage disequilibrium (r
2
) between TLR9 SNPs 
 rs353547 rs11717574 rs352143 +2848 rs352163 
rs353547  0.11 0.01 0.53 0.45 
rs11717574   0.65 0.13 0.13 
rs352143    0.21 0.21 
+2848     0.89 
rs352163      
 
TABLE E7. Association between CD14 genotype and asthma 
SNP Nonasthmatics, n (%) Asthmatics, n (%) OR (95%CI) 
CD14/-260    
 TT 133 (24.0) 67 (30.0) 1.00 
 CT 276 (49.8) 107 (48.0) 0.75 (0.51-1.10) 
 CC 145 (26.2) 49 (22.0) 0.66 (0.43-1.02) 
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 C allele 
¶
   0.81 (0.65-1.01) 
CD14/+1188    
 CC 428 (76.3) 181 (81.5) 1.00 
 CG 122 (21.8) 37 (16.7) 0.71 (0.48-1.06) 
 GG 11 (2.0) 4 (1.8) 0.85 (0.27-2.69) 
 CG+GG vs CC (ref)   0.72 (0.49-1.06) 
CD14/+1341    
 CC 292 (52.4) 131 (58.5) 1.00 
 AC 214 (38.4) 76 (33.9) 0.78 (0.56-1.09) 
 AA 51 (9.2) 17 (7.6) 0.74 (0.42-1.30) 
 AC+AA vs CC (ref)   0.77 (0.56-1.06) 
rs778584    
 CC 146 (25.1) 69 (29.0) 1.00 
 CT 286 (49.2) 117 (49.2) 0.85 (0.59-1.23) 
 TT 149 (25.7) 52 (21.9) 0.73 (0.48-1.12) 
 T allele 
¶
   0.86 (0.69-1.06) 
rs778583    
 CC 303 (52.0) 137 (57.3) 1.00 
 CT 226 (38.8) 85 (35.6) 0.82 (0.60-1.14) 
 TT 54 (9.3) 17 (7.1) 0.70 (0.39-1.22) 
 CT+TT vs CC (ref)   0.80 (0.59-1.09) 
¶ 
Additive genetic model, the genotype was categorized into a three level variable for the number of minor 
alleles (0,1,2). 
Ref: reference genotype coded as 0. 
 
TABLE E8. Association between TLR2 genotype and asthma 
SNP Nonasthmatics, n (%) Asthmatics, n (%) OR (95%CI) 
TLR2/-24438    
 AA 192 (33.2) 94 (39.3) 1.00 
 AG 286 (49.5) 120 (50.2) 0.86 (0.62-1.21) 
 GG 100 (17.3) 25 (10.5) 0.52 (0.31-0.86) 
 GG vs AA+AG (ref)   0.57 (0.36-0.90) 
TLR2/+596    
 TT 207 (36.6) 52 (23.3) 1.00 
 CT 259 (45.8) 122 (54.7) 1.88 (1.30-2.71) 
 CC 99 (17.5) 49 (22.0) 1.99 (1.24-3.19) 
 CT+CC vs TT (ref)   1.91 (1.34-2.72) 
TLR2/+1349    
 TT 502 (86.1) 199 (83.3) 1.00 
 CT 77 (13.2) 36 (15.1) 1.20 (0.79-1.85) 
 CC 4 (0.7) 4 (1.7) 2.58 (0.64-10.39) 
 C allele 
¶
   1.30 (0.90-1.88) 
TLR2/+1622    
 CC 515 (91.3) 201 (90.5) 1.00 
 CT 49 (8.7) 21 (9.5) 1.10 (0.64-1.92) 
rs2289318    
 CC 419 (71.9) 154 (64.4) 1.00 
 CG 145 (24.9) 81 (33.9) 1.51 (1.08-2.10) 
 GG 19 (3.3) 4 (1.7) 0.57 (0.19-1.72) 
 CG+GG vs CC (ref)   1.40 (1.01-1.94) 
¶ 
Additive genetic model, the genotype was categorized into a three level variable for the number of minor 
alleles (0,1,2). 
Ref: reference genotype coded as 0. 
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TABLE E9. Association between TLR4 genotype and asthma 
 
SNP Nonasthmatics, n (%) Asthmatics, n (%) OR (95%CI) 
rs10759930    
 CC 192 (32.9) 88 (36.8) 1.00 
 CT 305 (52.3) 107 (44.8) 0.76 (0.55-1.06) 
 TT 86 (14.8) 44 (18.4) 1.14 (0.73-1.78) 
 TT vs CC+CT (ref)   1.34 (0.88-2.03) 
rs2737191    
 AA 299 (51.4) 123 (51.5) 1.00 
 AG 248 (42.6) 101 (42.3) 0.99 (0.73-1.34) 
 GG 35 (6.0) 15 (6.3) 1.00 (0.52-1.89) 
 AG+GG vs AA (ref)   0.99 (0.74-1.32) 
TLR4 Thr399Ile    
 CC 492 (86.6) 198 (88.4) 1.00 
 CT 76 (13.4) 26 (11.6) 0.85 (0.52-1.39) 
rs7869402    
 CC 544 (96.3) 211 (93.8) 1.00 
 CT 21 (3.7) 13 (5.8) 1.56 (0.78-3.12) 
 TT 0 (0.0) 1 (0.4) n.e. 
rs11536889    
 GG 385 (66.2) 174 (73.1) 1.00 
 CG 183 (31.4) 55 (23.1) 0.69 (0.48-0.99) 
 CC 14 (2.4) 9 (3.8) 1.63 (0.64-4.11) 
 CG+CC vs GG (ref)   0.72 (0.51-1.00) 
rs1927906    
 AA 482 (82.7) 196 (82.4) 1.00 
 AG 99 (17.0) 39 (16.4) 0.97 (0.65-1.47) 
 GG 2 (0.3) 3 (1.3) 3.33 (0.58-19.08) 
 AG+GG vs AA (ref)   1.03 (0.69-1.53) 
rs1554973    
 TT 332 (57.4) 140 (58.6) 1.00 
 CT 219 (37.9) 83 (34.7) 0.92 (0.67-1.26) 
 CC 27 (4.7) 16 (6.7) 1.39 (0.75-2.59) 
 CC vs TT+CT (ref)   1.44 (0.79-2.64) 
rs913930    
 TT 252 (43.3) 99 (41.6) 1.00 
 CT 270 (46.4) 113 (47.5) 1.06 (0.78-1.45) 
 CC 60 (10.3) 26 (10.9) 1.07 (0.64-1.78) 
 CT+CC vs TT (ref)   1.06 (0.79-1.43) 
rs1927905    
 AA 513 (88.0) 208 (87.0) 1.00 
 AG 69 (11.8) 29 (12.1) 1.06 (0.67-1.66) 
 GG 1 (0.2) 2 (0.8) 4.62 (0.44-49.07) 
 AG+GG vs AA (ref)   1.11 (0.72-1.72) 
rs7045953    
 AA 415 (71.3) 174 (72.8) 1.00 
 AG 157 (27.0) 60 (25.1) 0.92 (0.66-1.29) 
 GG 10 (1.7) 5 (2.1) 1.21 (0.45-3.21) 
 GG vs AA+AG (ref)   1.23 (0.47-3.26) 
Ref: reference genotype coded as 0 
n.e. not estimable 
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TABLE E10. Association between TLR9 genotype and asthma 
 
SNP Nonasthmatics, n (%) Asthmatics, n (%) OR (95%CI) 
rs353547    
 GG 233 (40.0) 76 (31.9) 1.00 
 AG 263 (45.1) 124 (52.1) 1.46 (1.04-2.07) 
 AA 87 (14.9) 38 (16.0) 1.35 (0.85-2.15) 
 AG+AA vs GG (ref)   1.43 (1.03-1.99) 
rs11717574    
 TT 419 (72.5) 171 (72.2) 1.00 
 CT 140 (24.2) 62 (26.2) 1.08 (0.77-1.53) 
 CC 19 (3.3) 4 (1.7) 0.52 (0.17-1.55) 
 CC vs TT+CT (ref)   0.51 (0.17-1.51) 
rs352143    
 AA 370 (63.5) 144 (60.3) 1.00 
 AG 180 (30.9) 83 (34.7) 1.19 (0.87-1.64) 
 GG 33 (5.7) 12 (5.0) 0.92 (0.47-1.83) 
 AG+GG vs AA (ref)   1.15 (0.85-1.55) 
TLR9/+2848    
 GG 154 (27.6) 65 (29.6) 1.00 
 AG 275 (49.3) 118 (53.6) 1.00 (0.70-1.44) 
 AA 129 (23.1) 37 (16.8) 0.65 (0.40-1.07) 
 AA vs GG+AG (ref)   0.65 (0.43-0.99) 
rs352163    
 CC 159 (27.4) 67 (28.3) 1.00 
 CT 286 (49.3) 128 (54.0) 1.06 (0.75-1.50) 
 TT 135 (23.3) 42 (17.7) 0.73 (0.46-1.16) 
 T allele 
¶
   0.87 (0.70-1.09) 
¶ 
Additive genetic model, the genotype was categorized into a three level variable for the number of minor 
alleles (0,1,2). 
Ref: reference genotype coded as 0 
 
TABLE E11. Gene-environment interactions between CD14, TLR2, TLR4, and TLR9 SNPs and country living 
before 1 year in asthma outcomes, shown as associations between country living before 1 year and asthma, 
stratified by genotype 
   Living in the country before 1 year, OR (95% CI) 
Gene SNP  Genotype Asthma 
Asthma in atopic 
subjects 
Asthma in nonatopic 
subjects 
CD14 -260 TT+CT 0.70 (0.48-1.03) 0.92 (0.53-1.60) 0.54 (0.28-1.06) 
  CC 0.80 (0.38-1.70) 0.31 (0.09-1.07) 2.30 (0.80-6.66) 
 +1341 CC 0.90 (0.57-1.41) 1.13 (0.57-2.27) 0.76 (0.36-1.61) 
  AC+AA 0.53 (0.31-0.92) 0.48 (0.21-1.08) 0.83 (0.36-1.92) 
 rs778584 CC+CT 0.69 (0.47-1.01) 0.88 (0.51-1.52) 0.58 (0.30-1.09) 
  TT 0.90 (0.43-1.86) 0.32 (0.09-1.11) 2.10 (0.75-5.84) 
 rs778583 CC 0.83 (0.53-1.30) 1.12 (0.56-2.23) 0.69 (0.33-1.43) 
  CT+TT 0.60 (0.36-1.01) 0.44 (0.20-0.97) 1.00 (0.46-2.20) 
      
TLR2 -24438 AA+AG 0.66 (0.46-0.96) 0.85 (0.49-1.46) 0.57 (0.31-1.04)
*
 
  GG 1.41 (0.58-3.46) 0.42 (0.12-1.46) 7.07 (1.42-35.3) 
 +596 TT 0.88 (0.45-1.74) 0.42 (0.14-1.22) 2.49 (0.93-6.66)
*
 
  CT+CC 0.69 (0.46-1.05) 1.00 (0.56-1.81) 0.48 (0.24-0.96) 
 +1349 TT 0.71 (0.49-1.03) 0.69 (0.41-1.18) 0.95 (0.52-1.75) 
  CT+CC 0.79 (0.34-1.86) 1.17 (0.30-4.58) 0.34 (0.10-1.13) 
      
TLR4 rs11536889 GG 0.77 (0.52-1.15) 0.91 (0.50-1.65) 0.83 (0.45-1.53) 
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  CG+CC 0.60 (0.30-1.18) 0.52 (0.20-1.39) 0.66 (0.22-2.01) 
 rs7045953 AA 0.56 (0.38-0.85) 0.64 (0.36-1.15) 0.56 (0.29-1.09) 
  AG+GG 1.34 (0.71-2.55) 1.00 (0.37-2.66) 1.73 (0.66-4.57) 
      
TLR9 rs353547 GG+AG 0.84 (0.59-1.21) 1.09 (0.62-1.92)
*
 0.82 (0.47-1.45) 
  AA 0.28 (0.11-0.73) 0.12 (0.03-0.48) 0.80 (0.19-3.30) 
Bold: interaction p<0.05, not adjusted for multiple comparisons; 
*
 interaction p<0.10, FDR adjusted p value 
 
REFERENCES 
E1. Kauffmann F, Dizier MH, Pin I, Paty E, Gormand F, Vervloet D, Bousquet J, Neukirch F, Annesi I, 
Oryszczyn MP, et al. Epidemiological study of the Genetics and Environment of Asthma, bronchial 
hyperresponsiveness, and atopy: Phenotype issues. Am J Respir Crit Care Med 1997;156:S123-129. 
E2. Kauffmann F, Oryszczyn MP, Maccario J. The protective role of country living on skin prick tests, 
immunoglobulin e and asthma in adults from the epidemiological study on the genetics and environment 
of asthma, bronchial hyper-responsiveness and atopy. Clin Exp Allergy 2002;32:379-386. 
E3. Siroux V, Le Moual N, Rage E, Ferran J, Bousquet J, Gormand F, Just J, Nadif R, Oryszczyn MP, 
Ravault C, et al. Twelve-year follow-up of asthma, FEV1 and bronchial-hyperresponsiveness in children 
and adults in the Epidemiological study on Genetics and Environment of asthma, bronchial 
hyperresponsiveness and atopy – Preliminary results [abstract]. Am J Respir Crit Care Med 
2007;175:A828. 
E4. Horvath S, Xu X, Laird NM. The family based association test method: strategies for studying general 
genotype--phenotype associations. Eur J Hum Genet 2001;9:301-306. 
 
 
